Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CANCER THERAPY

Molecular profiling in precision medicine oncology

Three innovative precision medicine studies show the utility of evidence beyond that from tumor DNA sequencing to guide therapy in patients with cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: New concepts evaluated in the I-PREDICT, TARGET and WINTHER studies.

References

  1. 1.

    Yates, L. R. Ann. Oncol. 29, 30–35 (2018).

    CAS  Article  Google Scholar 

  2. 2.

    Le, D. T. New Engl. J. Med. 372, 2509–2520 (2015).

    CAS  Article  Google Scholar 

  3. 3.

    Drilon, A. New Engl. J. Med. 378, 731–739 (2018).

    CAS  Article  Google Scholar 

  4. 4.

    Rothwell, D. G. Nat. Med. https://doi.org/10.1038/s41591-019-0380-z (2019).

  5. 5.

    Sicklick, J. K. Nat. Med. https://doi.org/10.1038/s41591-019-0407-5 (2019).

  6. 6.

    Rodon, J. Nat. Med. https://doi.org/10.1038/s41591-019-0424-4 (2019).

  7. 7.

    von Hoff, D. D. J. Clin. Oncol. 28, 4877–4883 (2010).

    Article  Google Scholar 

  8. 8.

    Stockley, T. L. Genome Med. 8, 109 (2016).

    Article  Google Scholar 

  9. 9.

    Le Tourneau, C. Lancet Oncol. 16, 1324–1334 (2015).

    Article  Google Scholar 

  10. 10.

    Belin, L. Ann. Oncol. 28, 590–596 (2017).

    CAS  PubMed  Google Scholar 

  11. 11.

    Massard, C. Cancer Disco. 7, 586–595 (2017).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

All authors contributed to the writing of the manuscript.

Corresponding author

Correspondence to Christophe Le Tourneau.

Ethics declarations

Competing interests

C.L.T. has received consultant fees from Merck Serono, Merck & Co., Bristol-Myers Squibb, Amgen, Novartis, GlaxoSmithKline and Roche.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Le Tourneau, C., Borcoman, E. & Kamal, M. Molecular profiling in precision medicine oncology. Nat Med 25, 711–712 (2019). https://doi.org/10.1038/s41591-019-0442-2

Download citation

Further reading

Search

Quick links